Completed × Lung Neoplasms × Erlotinib Hydrochloride × Clear all A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC)
Phase 1/2 Completed
92 enrolled 14 charts
BM
Phase 2/3 Completed
492 enrolled
A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib
Phase 1/2 Completed
24 enrolled 8 charts
BLISS
Phase 2 Completed
154 enrolled
MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy
Phase 1/2 Completed
31 enrolled
A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation
Phase 1 Completed
43 enrolled
BELIEF
Phase 2 Completed
109 enrolled 20 charts
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
Phase 2 Completed
334 enrolled 14 charts
ENCORE110
Phase 1 Completed
14 enrolled
Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer
Phase 2 Completed
44 enrolled 16 charts
Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer
Phase 1/2 Completed
222 enrolled 23 charts
Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment
Phase 2 Completed
201 enrolled 12 charts
Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Phase 1 Completed
17 enrolled 12 charts
A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
Phase 3 Completed
636 enrolled 14 charts
LADIE
Phase 2 Completed
379 enrolled
TARLAL
Phase 2 Completed
15 enrolled 6 charts
NVALT10
Phase 2 Completed
195 enrolled
Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 2 Completed
24 enrolled 12 charts
Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer
Phase 1/2 Completed
32 enrolled 13 charts
S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma
Phase 2 Completed
84 enrolled 15 charts
S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer
Phase 2 Completed
89 enrolled 11 charts
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Phase 2 Completed
59 enrolled 13 charts
BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Phase 2 Completed
37 enrolled 9 charts
TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)
Phase 2 Completed
68 enrolled 11 charts
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Phase 1 Completed
76 enrolled
A Single-Dose,ComparativeBioavailability Study ofTwo Formulations ofErlotinib150mgTabletsunderFastingConditions
Phase 4 Completed
24 enrolled
Bevacizumab and Erlotinib Followed by Cisplatin or Carboplatin and Gemcitabine in Treating Patients With Newly Diagnosed or Recurrent Stage IIIB or Stage IV NSCLC
Phase 2 Completed
104 enrolled
Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).
Phase 2 Completed
149 enrolled
Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Phase 2 Completed
108 enrolled
Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Phase 2 Completed
86 enrolled 9 charts
Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
Phase 1/2 Completed
81 enrolled 14 charts
Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer
Phase 1/2 Completed
41 enrolled
SELECT
Phase 2 Completed
25 enrolled
Erlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON)
Phase 2 Completed
9 enrolled 6 charts
Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers
Phase 2 Completed
38 enrolled 13 charts
BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC
Phase 2 Completed
59 enrolled 7 charts
Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer
Phase 1/2 Completed
46 enrolled 15 charts
Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Phase 2 Completed
116 enrolled 11 charts
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
Phase 2 Completed
89 enrolled 28 charts
Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer
Phase 1/2 Completed
64 enrolled 11 charts
Ph II Gemcitabine, Erlotinib, and Gemcitabine With Erlotinib/Elderly Patients W/ IIIB/IV NSCLC
Phase 2 Completed
147 enrolled 16 charts
A Study of MetMAb Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib)
Phase 2 Completed
137 enrolled 11 charts
A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer
Phase 1/2 Completed
162 enrolled 11 charts
Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)
Phase 1/2 Completed
53 enrolled 10 charts
MIMEB
Phase 2 Completed
40 enrolled
Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer
Phase 2 Completed
25 enrolled 12 charts
Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients
Phase 4 Completed
54 enrolled
Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
Phase 2 Completed
202 enrolled 8 charts
Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer
Phase 1 Completed
27 enrolled 22 charts
Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Phase 2 Completed
46 enrolled 12 charts